

## Research Article



## Comparative Study of Different Formulations of Chlorpheniramine Maleate Orally Disintegrating Tablets

Amar Issa<sup>a\*</sup>, Oussama Mansour<sup>b</sup>, Tamim Hammad<sup>a</sup>

a. Department of Pharmaceutics, Faculty of Pharmacy, Tishreen University, Latakia, Syria.

b. Department of Medicinal Chemistry and quality Control, Faculty of Pharmacy, Tishreen University, Latakia, Syria.

\*Corresponding author's E-mail: [ws.sarah2005@gmail.com](mailto:ws.sarah2005@gmail.com)

Accepted on: 12-08-2014; Finalized on: 30-09-2014.

### ABSTRACT

Patient compliance is a key factor in recovery or healing, and hard-to-swallow tablets are one of barriers against patient compliance. The purpose of this study is to formulate and evaluate different formulations of Orally Disintegrating Tablets (ODTs) of Chlorpheniramine Maleate. Tablets were prepared by the direct compression method. Three types of diluents were used: lactose, mannitol, and glucose. For each group, 40 mg of five different disintegrants such as crospovidone (kollidon-CL<sup>®</sup>), microcrystalline cellulose, microcrystalline cellulose, sodium starch glycolate, and sodium croscarmillose were experimented. The lowest disintegration time (17±2.5 sec) was found in the formulation which contains glucose as a diluent and kollidon-CL<sup>®</sup> as a disintegrant. Followed by the formulation which contains mannitol as a diluent and kollidon-CL<sup>®</sup> as a disintegrant with a disintegration time of 21.16±3.5 sec. These formulations also showed the highest dissolution rate, compared to other formulations. All tablets had a uniform weight and content. They had good mechanical strength, and all of them released 80% of their chlorpheniramine maleate's content in less than 30 minutes. Tablets with lower disintegrating time released their active ingredient in less time.

**Keywords:** Orally Disintegrating Tablets, Chlorpheniramine Maleate, Disintegrants, Diluents, Disintegration time.

### INTRODUCTION

One of the greatest challenges facing the pharmaceutical industry today is how to make drugs easy to take so that patients positively enjoy the experience.<sup>1-3</sup> Hard-to-swallow tablets are one of the key barriers to patient compliance, and to obviate this problem, researchers have developed a new dosage form called Orally Disintegrating Tablets (ODTs) which disintegrate in mouth rapidly, usually within a matter of seconds, when placed upon the tongue without the need for water.<sup>4-6</sup> Thus they are suitable for geriatric, pediatric, and traveling patients who suffer from inaccessibility to water.<sup>7,8</sup> In addition to that, ODTs are able to release the active ingredients rapidly, giving the fast effect that needed for some cases like allergy, pain, and anxiety.<sup>9</sup> Moreover, drug candidates which undergo pre-gastric absorption when formulated as orally disintegrating tablets may show increased oral bioavailability.<sup>10,11</sup>

The US FDA ODT guideline suggests 30 seconds (*in vitro*) as the preferred disintegration time whereas the disintegration time recommended by European pharmacopoeia is less than 3minutes.

Although different technologies, including molding, sublimation, direct compression, wet granulation, freeze drying and spray drying, have been used to prepare ODTs and have advanced considerably along with the rapid market growth of ODTs product, the direct compression method was reported as the simplest and most cost-effective ODTs manufacturing procedure. Moreover, the ODTs prepared by direct compression shows better physical strength than those prepared by other methods.<sup>12-14</sup>

The pharmaceutical active ingredients, which have been formulated as ODTs, are still limited worldwide, in spite of their features and benefits. Hence, the present work aims to prepare and study different formulations of Orally Disintegrating Tablets of chlorpheniramine maleate by direct compression method.

Chlorpheniramine maleate is a first-generation alkylamine antihistamine used as a treatment of allergic conditions such as rhinitis and urticaria. It's known as OTC sedative drug because it passes the blood brain barrier.<sup>15-17</sup> In addition, Chlorpheniramine maleate has been proved to have an antidepressant property.<sup>18</sup> The bioavailability of chlorpheniramine maleate is 0.4 and its half time is about 30 hours. Chlorpheniramine maleate is freely soluble in water and has a pKa=9.2.<sup>19-21</sup> Chlorpheniramine maleate does not exist in such dosage form.

### MATERIALS AND METHODS

#### Materials

Chlorpheniramine maleate was received as a gift sample from Syphcopharma, Syria. Super disintegrants such as: Crospovidone (Kollidon-CL<sup>®</sup>: polyplasdon XL-10), Microcrystalline Cellulose (Avicel PH 101<sup>®</sup> and Avicel PH 102<sup>®</sup>), Sodium Croscarmillose (Ac-di-sol<sup>®</sup>) were obtained as gift samples from Alpha Pharmaceutical Industries, Aleppo, Syria. All other materials like lactose, mannitol, glucose, sodium saccharin, Aerosil 200 and analytical solutions were of analytical grade.

#### Preparation of Orally Disintegrating Tablets

Chlorpheniramine maleate ODTs were prepared by direct compression method according to this united formula:



Chlorpheniramine Maleate	4 mg
Disintegrant	40 mg
Diluent	238 mg
Aerosil200	1% (3 mg)
Sweetener (Sodium Saccharine)	15 mg

Fifteen prepared formulations which have different diluents and/or different disintegrants are given in **Table 1**.

**Table 1:** Various formulations of Chlorpheniramine Maleate ODTs.

mg/ 300mg	Chlorpheniramine maleate	lactose	mannitol	Glucose	Kollidon CL	Avicel Ph102	Avicel Ph101	Promojel	Ac- Di- Sol	Sodium Saccharin	Aerosil200
A1	4	238	-	-	40	-	-	-	-	15	3
A2	4	238	-	-	-	40	-	-	-	15	3
A3	4	238	-	-	-	-	40	-	-	15	3
A4	4	238	-	-	-	-	-	40	-	15	3
A5	4	238	-	-	-	-	-	-	40	15	3
B1	4	-	238	-	40	-	-	-	-	15	3
B2	4	-	238	-	-	40	-	-	-	15	3
B3	4	-	238	-	-	-	40	-	-	15	3
B4	4	-	238	-	-	-	-	40	-	15	3
B5	4	-	238	-	-	-	-	-	40	15	3
C1	4	-	-	238	40	-	-	-	-	15	3
C2	4	-	-	238	-	40	-	-	-	15	3
C3	4	-	-	238	-	-	40	-	-	15	3
C4	4	-	-	238	-	-	-	40	-	15	3
C5	4	-	-	238	-	-	-	-	40	15	3

All ingredients were weighed and mixed uniformly together. The obtained blend was lubricated with aerosol 200. The tablets were compressed using single punch tablet compression machine to get a tablet of 300 mg weight containing 4 mg of chlorpheniramine maleate.

The prepared tablets were divided to three groups of three different diluents:

Group A contains lactose

Group B contains mannitol

Group C contains glucose

For each group, five different super disintegrants were used:

Crospovidon (Kollidon-CL<sup>®</sup>: PolyplasdonXL-10), Microcrystalline Cellulose (AvicelPH 102<sup>®</sup>), Microcrystalline Cellulose (AvicelPH 101<sup>®</sup>), Sodium Starch Glycolate (Primojel<sup>®</sup>) and Sodium Croscarmillose (Ac-di-sol<sup>®</sup>). The other ingredients like sodium saccharin as a sweetener and aerosil 200 as a lubricant were kept constant.

## Evaluation of prepared tablets

### Weight Uniformity

Twenty randomly selected tablets were weighed individually. The average weight and the standard deviation were calculated.

None of the tablets should deviate from the average weight by more than  $\pm 10\%$  as indicated in the European pharmacopeia, 2005.<sup>12</sup>

### Content uniformity

The content uniformity test is used to ensure that every tablet contains the amount of drug substance intended with little variation among tablets within a batch.

Ten tablets were selected at random and HPLC (High Performance Liquid Chromatography) analytical method was applied to assay the individual content of the active ingredient in each tablet by pulverizing it to a fine powder and solute it in 500 ml of HCl 0.01M as indicated in the USP-NF. 30<sup>th</sup> ed., 2007.<sup>22</sup>

The preparation complies if not more than one (all within limits) individual content is outside the limits of 85 to 115% of the average content and none is outside the limits of 75 to 125% of the average content.

### Hardness and friability tests

Hardness or crushing strength of the tested Orally Disintegrating Tablet formulations was measured using the hardness tester (Erweka D-63150: GmbH/TBH.200, Germany) as indicated by Niazi, 2004.

The friability of a sample of 20 orally disintegrating tablets was measured utilizing a LOGAN instrument corp. FAB-2. Pre-weighed tablets were placed in a plastic chambered friabilator attached to a motor revolving at a speed of 25 rpm for 4 min.<sup>23</sup> The tablets were then de-dusted, reweighed, and percentage weight loss (friability) was calculated by the equation.

$$\% \text{Friability} = \frac{\text{Loss in weight}}{\text{Initial weight}} \times 100$$

### In-vitro Disintegration test

*In vitro* disintegration time (DT) of the orally disintegrating tablets was determined by placing 10 mL of phosphate buffer (pH= 7.2) at 25°C in a petri dish of 10 cm diameter.<sup>24-27</sup> The tablet was then carefully positioned in the center of the petri dish and the time required for the tablet to completely disintegrate into fine particles was noted. Measurements were carried out in replicates of six tablet (n=6) and mean SD values were recorded.

### Dissolution Test

Dissolution test of Chlorpheniramine maleate tablets was performed according to USP XVIII apparatus II, paddle method (Erweka DT600). Paddle speed was maintained at 50 rpm and 500 mL of 0.01M HCl was used as the dissolution medium. Samples (5mL) were collected at



predetermined time intervals (1, 2, 3, 4, 5, 7, 10, 15, 20 and 30 min), replaced with equal volume of fresh medium, and analyzed with HPLC analytical method.<sup>22,28-30</sup>

### Assay

HPLC analytical method was used, and a calibration curve was drawn by a series of Chlorpheniramine maleate standard solutions which was prepared from a mother solution (28mg/100ml).

A standard solution for each used excipient was also prepared and analyzed by HPLC method to get their chromatogram.<sup>22,28,29</sup>

### HPLC Parameters

HPLC was performed on C-18 column following the parameters developed by Maithani et al., 2010. 20 µL of the sample was injected and the analysis was carried using phosphate buffer (pH=5.8): acetonitrile (55:45) as a mobile phase at a flow rate of 1 ml/min. Detection was accomplished by UV spectrophotometer at 255 nm.

## RESULTS AND DISCUSSION

### Chlorpheniramine Maleate assay

The typical calibration curve for Chlorpheniramine Maleate analyzed by HPLC method and detected by UV spectrophotometer was:

$$y = 116656x - 3775.8$$

$$R^2 = 0.9966$$

HPLC showed that all excipients except sodium saccharine had no absorbance of U.V at the same wavelength with chlorpheniramine maleate, this result matches with that obtained by Dibbern et al., 2002.<sup>31</sup> Hence, HPLC method can cancel this U.V absorption interference and gives accurate assay results.

### Evaluation of Prepared Tablets

The data obtained from post-compression parameters such as weight variation, drug content, hardness, friability were all in boundary of standard limit.

All the tablets passed weight variation test as the percentage weight variation was within the pharmacopoeial limits.

The percentages drug contents of all the tablets were found to be in the acceptable limits.

The hardness of all prepared tablets were found to be in the range of 3.75±0.42 to 15.3±1.51 kg/cm<sup>2</sup>.

In all the formulations the loss in total weight of the tablets due to friability was less than 1% (in the range of 0.4-0.96%).

The last two parameters indicated good mechanical strength with an ability to withstand physical and mechanical stress conditions while handling.

Disintegration time was found in the range of 17 ± 2.5sec to 3.13min±16.32sec **Tables 2**.

**Table 2:** Disintegration Time of Group A, B and C Formulations prepared by lactose, mannitol and glucose respectively.

Formulation	Disintegrant	Disintegration Time
A <sub>1</sub>	Kollidon CL	35.16 ± 3.6sec
A <sub>2</sub>	Avicel PH 102	3.13min ± 16.32sec
A <sub>3</sub>	Avicel PH 101	3.02min ± 16.04sec
A <sub>4</sub>	Primojel	56.66 ± 4.63sec
A <sub>5</sub>	Ac-Di-Sol	55.66 ± 6.05sec
B <sub>1</sub>	Kollidon CL	21.16 ± 3.5sec
B <sub>2</sub>	Avicel PH 102	3.07min ± 14.71sec
B <sub>3</sub>	Avicel PH 101	2.38min ± 12.9sec
B <sub>4</sub>	Primojel	45 ± 4.47sec
B <sub>5</sub>	Ac-Di-Sol	40.33 ± 5.08sec
C <sub>1</sub>	Kollidon CL	17 ± 2.5sec
C <sub>2</sub>	Avicel PH 102	2.54min ± 8.65sec
C <sub>3</sub>	Avicel PH 101	2.21min ± 17.7sec
C <sub>4</sub>	Premojel	37.83 ± 3.18sec
C <sub>5</sub>	Ac-Di-Sol	33.83 ± 2.92sec

Comparative study of ODTs combinations prepared by the same superd is integrant and different diluents, showed that the least disintegration time was for group C prepared by glucose as a diluent, followed by group B prepared by mannitol, then group A prepared by lactose, respectively. This might be due to the high solubility of glucose compared to the other two diluents.<sup>32</sup>

Glucose solubility: 1g/1ml water.  
 Mannitol solubility: 1g/ 5.5ml water.  
 Lactose solubility: 1g/ 10-30ml water.

Generally, mannitol is desirable in orally disintegrating dosage forms, because it gives good mouth feel and a pleasant sweet taste. While comparing the disintegration time values of different groups to each other, tablet which contain Kollidon-CL as a disintegrant exhibited the least disintegration time (17±2.5 sec, 21.16±3.5 sec, and 35.16±3.6 sec for formulations C1, B1 and A1, respectively) compared to other formulations in the same group. This might be due to high porosity of Kollidon- CL which is a cross-linked synthetic polymer.<sup>32</sup> Hence, water can get throw the pores rapidly exhibiting high capillary activity. That can accelerate tablet swelling and disintegration with little tendency to form gels. Additionally, as Kollidon-CL is non-ionic compound, the disintegration is independent of the acidity of gastrointestinal tract.

Formulations prepared by Ac-di-sol were in the second place of disintegration time (33.83±2.92 sec, 40.33±5.08 sec, and 55.66±6.05 sec for C5, B5 and A5, respectively).




The disintegration time of tablets prepared by Kollidon-CL® was shorter than those prepared by Ac-di-sol because of the inner adhesive, fibrous and non-porous structure of Ac-di-sol.<sup>32,33</sup> Hence, the intramolecular bounds must be broken and a hydrophilic network have to be formed for the swelling and disintegration of tablet. This may delay tablet disintegration.

Tablets prepared by primojel were in the third place of disintegration time ( $37.83 \pm 3.18$  sec,  $45 \pm 4.47$  sec, and  $56.66 \pm 4.63$  sec for C4, B4 and A4, respectively). This might be due to the non-porous structure of primojel and its gel-forming tendency which may reduce the ability of swelling and disintegrating.


The longest disintegration time found was more than 3 minutes and resulted from the use of Avicel. Those results emphase that the binding role of Avicel is stronger than its disintegrate effect which is also done by the mechanism of swelling.

Previous results concluded that the least disintegration time ( $17 \pm 2.5$  sec) was for the tablets prepared by Kollidon-CL as a disintegrant and glucose as a diluent, followed by tablets prepared by Kollidon-CL and mannitol ( $21.16 \pm 3.5$  sec).


In vitro dissolution studies are shown in **Figure 1** (a, b, c). The cumulative percentage of drug release were within pharmacopeia limits.<sup>22</sup>



**Figure 1 (a):** *In vitro* dissolution studies for group A formulations (prepared by lactose)



**Figure 1 (b):** *In vitro* dissolution studies for group B formulations (prepared by Mannitol).



**Figure 1 (c):** *In vitro* dissolution studies for group C formulations (prepared by Glucose).



As the dissolution of tablets depends on disintegration time, thus tablets with less disintegration time are capable to release their contents in shorter time, the dissolution test results obviously complied with the disintegration time of tablets.

In addition, as indicated by Rowe et al., 2009 and Balasubramaniam, 2009, the specific surface area of Kollidon-CL (polyplasdon XL- 10) is about 1.2-1.4 m<sup>2</sup>/g which is bigger than the other disintegrant such as Ac-di-sol and Primojel (0.81-0.83 m<sup>2</sup>/g and 0.185 m<sup>2</sup>/g for, respectively).<sup>32,34</sup> This fact can also explain the rapid dissolution of tablets prepared by Kollidon-CL compared to other disintegrant.

## CONCLUSION

The present investigation successfully formulates Orally Disintegrating tablets of Chlorpheniramine Maleate by direct compression method which is found to be useful to prepare ODTs with sufficient mechanical strength and short disintegration time. Among the prepared formulation, tablets prepared by Kollidon-CL<sup>®</sup> as a disintegrant and Glucose or Mannitol as diluent showed the best performance in disintegrant time (about 17 sec) compared to other formulations.

**Acknowledgement:** The authors would like to thank Syphcopharma (Syria) and Alpha Pharmaceutical Industries (Aleppo, Syria) for offering the active ingredient and all excipients used in this study. Writing assistance provided by Dr. Wissam Zam, from the Faculty of Pharmacy at Al-Andalus University (Syria) is greatly appreciated.

## REFERENCES

- Debjit B, Chiranjib B, Krishnakanth P, Margret Ch, Fast Dissolving Tablet: An Overview, Journal of Chemical and Pharmaceutical Research, 1(1), 2009, 163-177.
- Pahwa R, Piplani M, Sharma PC, Kaushik D, Sanju N, Orally Disintegrating Tablets - Friendly to Pediatrics and Geriatrics, Archives of Applied Science Research, 2(2), 2010, 35-48.
- Shailesh Sh, New Generation Of Tablet: Fast Dissolving Tablet, Pharmaceutical reviews, 6(1), 2008, 44-68.
- Deshpande KB, Ganesh NS, Orodispersible Tablets: An Overview Of Formulation And Technology, International Journal Of Pharma And Bio Sciences, 2(1), 2011, 726-734.
- McLaughlin R, Banbury S, Crowley K, Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications, Pharmaceutical Technology, 2009, <http://www.pharmatech.com>
- U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry Orally Disintegrating Tablets, Center for Drug Evaluation and Research (CDER), 2008, 1-6.
- Navarro V, Improving medication compliance in patients with depression: Use of orodispersible tablets, Adv.Ther., 27(11), 2010, 785-95.
- Reddy LH, Ghosh BR, Fast dissolving drug delivery systems: A review of the literature, Ind J Pharm Sci, 64(4), 2002, 331-336.
- Sharma S, Pharmainfo.net, 2009, <[www.pharmainfo.net/reviews/orodispersable-tablet-review](http://www.pharmainfo.net/reviews/orodispersable-tablet-review)>.
- Shyamala B, Narmada GY, Rapid Dissolving Tablets: A Novel Dosage Form. The Indian Pharmacist, 13(8), 2002, 9-12.
- Wagh MP, Yewale CP, Zate SU, Kothawade PI, Mahale GH, Formulation And Evaluation Of Fast Dispersible Tablets Of Aceclofenac Using Different Super disintegrant, International Journal of Pharmacy and Pharmaceutical Sciences, 2(1), 2010, 154-157.
- European pharmacopeia, 2005.
- Biradar SS, Bhagavati ST, Kuppasad IJ, Fast Dissolving Drug Delivery Systems: A Brief Overview, Internet J. Pharmacology, 4(2), 2006.
- FuY, Yang Sh, Hoon JS, Kimura S, Kinam P, Orally Fast Disintegrating Tablets: Developments, Technologies, Taste-Masking and Clinical Studies, Critical Reviews in Therapeutic Drug Carrier Systems USA, 21(6), 2004 433-475.
- Hirani JJ, Rathod DA, Vadalia KR, Orally Disintegrating Tablets: A Review. Tropical Journal of Pharmaceutical Research, 8(2), 2009, 161-172.
- Harvey R, Lippincott's Illustrate Reviews, Laale Professional, 3rd, 2006, 515-520.
- Lullman H, Mohr K, Ziegler A, Bieger D, Color Atlas Of Pharmacology, Thieme Stuttgart NewYork, 2<sup>nd</sup> edition, 2000, 114, 326.
- Olson J, Clinical Pharmacology, University Of Washington, 140-141.
- Webster DR, Paton DM, Clinical Pharmacokinetics Of H1-Receptor Antagonists (The Antihistamines), ClinPharmacokinet, 10(6), 1985, 477-97.
- Hasenöhrl RU, Weth K, Huston JP, Intraventricular infusion of the histamine H1 receptor antagonist chlorpheniramine improves maze performance and has anxiolytic-like effects in aged hybrid Fischer 344xBrown Norway rats, Pubmed Exp Brain Res, 128(4), 2012, 435-40.
- Wagh MA, Dilip KP, Salunkhe KS, Chavan NV, Daga VR, Techniques used in orally disintegrating drug delivery system, International Journal of Drug Delivery, 2, 2010, 98-107.
- USP-NF. 30<sup>th</sup> ed., 2007.
- Niazisk, Handbook Of Pharmaceutical Manufacturing Formulation, Taylor & Francis 2004.
- Alanazi F, Evaluation Of Spray And Freeze Dried Excipient Bases Containing Disintegrating Accelerators For The Formulation Of Metoclopramide Orally Disintegrating Tablets, Saudi Pharmaceutical Journal, 15(2), 2007, 105-119.
- Anupama K, Shelly Kh, Neena B, Formulation And Evaluation Of Mouth Dissolving Tablets Of Oxcarbazepine, International Journal of Pharmacy and Pharmaceutical Sciences, 1(1), 2009, 12-23.
- Shailendra K, Dina N, Rishab J, Pankaj S, Fast Disintegrating Combination Tablets Of Omeprazole And Domperidone, Asian Journal of Pharmaceutical and Clinical Research, 2(3), 2009, 74-82.
- Sunita AC, Tejal AM, Ankit BC, Formulation, Development and Evaluation Of Fast Disintegrating Tablets Of Rizatriptan Benzoate Using Novel Adjuvants, International Journal of Chem Tech Research, 2(2), 2010, 1026-1030



28. Maithani M, Raturi R, Gautam V, Kumar D, Chaudhary A, Gaurav A, Singh R, Development And Validation Of A Rp-Hplc Method For The Determination Of Chlorpheniramine Maleate And Phenylephrine In Pharmaceutical Dosage Form, *Pharmacie Globale International Journal Of Comprehensive Pharmacy* 1(5), 2010, 15-20.
29. British pharmacopiea, Vol III, London, 2009.
30. Klancke J, Dissolution Testing Of Orally Disintegrating Tablets, *Dissolution Technologies*, 10(2), 2010, 6-8.
31. Dibbern WH, Muller RM, Wirbitzki E, *UV and IR Spectra*, Editio Cantor Verlag, Frankfurt, 2002, 482.
32. Rowe R, Sheskey, Quinn ME, *Handbook of Pharmaceutical Excipients*, Pharmaceutical Press, USA, 6<sup>th</sup>ed., 2009, 206-208, 663.
33. Ferrero C, Munoz N, Velasco MV, Munuz-Ruiz A, Jimenez-Castellanos R, Disintegrating Efficiency Of Croscarmellose Sodium In A Direct compression formulation, *International Journal of Pharmaceutics Spain*, 147, 1997, 11-21.
34. Balasubramaniam J, Influence of Super disintegrants on the Rate of Drug Dissolution from Oral Solid Dosage Forms, 2009, <<http://mailto:tbee@ispcorp.com>>, India.

**Source of Support: Nil, Conflict of Interest: None.**

